faces a more urgent need to improve its pipeline than do its rivals. Its best-selling product, transplant drug Prograf, lost U.S. patent protection in April last year, although it still has no generic rivals. Second best-seller Flomax, used for urinary the once daily profile of LCP's extended release tablet formulation of tacrolimus when compared to twice daily Prograf(R) capsules. Expectations for 2009 LCP maintains its 2009 guidance with an operating loss of DKK 450 - 480 million and a net loss of Since people have been visiting the blog and asking when I'd write another post (even though most of those people we have seen in person on a regular basis and know the progress), here is the post. Big news is that Tri has gained 5 whole pounds. He still looks skinny, but it is pretty remarkable aft ...
No comments:
Post a Comment